BOSTON (Reuters) - A number of hedge funds sold positions in two drug companies leading the race to a coronavirus vaccine in the quarter before both announced breakthroughs that lifted their stock prices, while a few took stakes in the companies during that time.
Regulatory filings show that hedge funds sold millions of shares in drugmakers Moderna and BioNtech during the third quarter, missing out on big gains this month when each announced their vaccines are more than 94% effective.
Since the end of the third quarter BioNtech's stock has jumped another 26% and Moderna's stock has climbed 28%, adding to triple-digit percentage gains and putting them among the biggest winners this year, during which the S&P 500 has rebounded 60% from its March lows.
Moderna's stock price surged 376% since January while BioNtech's rose 157%, handily beating the S%P 500 index which is up 12%, having bounced back from deep losses earlier in 2020.
Original article:
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
더 오래된 의견은 없습니다. 소파를 가장 먼저 잡으십시오.